Anacor Pharmaceuticals Announces FDA Acceptance of Tavaborole NDA for Filing

  Anacor Pharmaceuticals Announces FDA Acceptance of Tavaborole NDA for Filing

Business Wire

PALO ALTO, Calif. -- October 1, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its New Drug
Application (NDA) for tavaborole, its drug candidate for the topical treatment
of onychomycosis, has been accepted by the U.S. Food and Drug Administration
(FDA) indicating that the application is sufficiently complete to permit a
substantive review. The Prescription Drug User Fee Act (PDUFA) V goal date is
July 29, 2014.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered seven compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 an antibiotic for the treatment of infections
caused by Gram-negative bacteria. We have discovered two other compounds that
we have out-licensed for further development — one compound for the treatment
of an animal health indication that is licensed to Eli Lilly and Company and
AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT,
or sleeping sickness), which is licensed to Drugs for Neglected Diseases
initiative, or DNDi. We also have a pipeline of other internally discovered
topical and systemic boron-based compounds in development. For more
information, visit http://www.anacor.com.

Forward-Looking Statements

This press release contains forward-looking statements with respect to the FDA
goal date for Anacor’s product candidate, tavaborole. These forward looking
statements involve known and unknown risks, uncertainties and other factors
that could cause actual levels of activity, performance or achievement to
differ materially from those expressed or implied by these forward-looking
statements, including risks related to the regulatory approval process of new
drug candidates. Reference should be made to Anacor's Annual Report on Form
10-K for the year endedDecember 31, 2012, filed with theSecurities and
Exchange Commissionunder the heading "Risk Factors" and Anacor's subsequent
Quarterly Reports on Form 10-Q for a more detailed description of such
factors. These statements reflect the views of Anacor as of the date of this
press release with respect to future events and, except as required by law, it
undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise
after the date of this press release.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
dsheel@anacor.com